Compare SR & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SR | IOVA |
|---|---|---|
| Founded | 1857 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 968.6M |
| IPO Year | N/A | N/A |
| Metric | SR | IOVA |
|---|---|---|
| Price | $83.03 | $2.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $87.00 | $10.45 |
| AVG Volume (30 Days) | 445.3K | ★ 11.3M |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | ★ 4.30 | N/A |
| EPS | ★ 4.37 | N/A |
| Revenue | ★ $2,476,400,000.00 | $250,425,000.00 |
| Revenue This Year | $13.96 | $60.94 |
| Revenue Next Year | $9.43 | $60.85 |
| P/E Ratio | $18.89 | ★ N/A |
| Revenue Growth | N/A | ★ 175.62 |
| 52 Week Low | $64.54 | $1.64 |
| 52 Week High | $91.11 | $8.15 |
| Indicator | SR | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 41.86 | 66.72 |
| Support Level | $82.01 | $2.08 |
| Resistance Level | $85.03 | $2.60 |
| Average True Range (ATR) | 1.44 | 0.15 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 31.99 | 96.38 |
Spire Inc. is the holding company for Spire Missouri, Spire Alabama, other gas utilities, and gas-related businesses, focused on growing organically, investing in infrastructure, and advancing through innovation. Its three segments are Gas Utility, Gas Marketing, and Midstream. The Gas Utility segment is the core business and includes Spire Missouri, Spire Alabama, and Spire EnergySouth. The Gas Marketing segment includes Spire Marketing, which provides non-regulated natural gas services across the U.S. The Midstream segment includes Spire Storage, Spire STL Pipeline, and Spire MoGas Pipeline. The majority of revenue comes from Gas Utility.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.